BTIG analyst Thomas Shrader maintained a Buy rating on Ovid Therapeutics (OVID – Research Report) yesterday and set a price target of $5.00. Thomas Shrader’s rating is based on a combination ...
ANN ARBOR – Call it a supersized slumber party. Dozens of local high school students travelled to Ann Arbor recently, courtesy of the Cook Family Foundation.